Results 121 to 130 of about 118,308 (164)

Phase IIa Study of the CD19 Antibody MOR208 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Annals of Oncology, 2018
Mariano Provencio, Pier Luigi Zinzani, Tadeusz Robak   +2 more
exaly  

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

New England Journal of Medicine, 2020
Homer A Macapinlac, Yago Nieto, Rohtesh S Mehta   +2 more
exaly  

T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial

Lancet, The, 2015
Crystal Mackall, Terry J Fry, Alan S Wayne   +2 more
exaly  

Treating B-Cell Cancer With T Cells Expressing Anti-CD19 Chimeric Antigen Receptors

Nature Reviews Clinical Oncology, 2013
James N Kochenderfer, Steven Rosenberg
exaly  

B-Cell Depletion and Remissions of Malignancy Along With Cytokine-Associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor–Transduced T Cells

Blood, 2012
James N Kochenderfer, Steven A Feldman, Mark E Dudley   +2 more
exaly  

CD19 variants

2019
LOBB ROY, RENNERT PAUL, HACKEL BENJAMIN, KLESMITH JUSTIN   +3 more
openaire   +4 more sources

CD19

2016
openaire   +1 more source

Chimeric Antigen Receptor T Cells Against CD19 for Multiple Myeloma

New England Journal of Medicine, 2015
Bruce L. Levine, Adam Bagg, Yolanda Mahnke   +2 more
exaly  

Anti-CD19 antibodies

2009
HANSEN HANS J, QU ZHENGXING, GOLDENBERG DAVID M   +2 more
openaire   +12 more sources

Assessment and Management of Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T Cell Therapy

Expert Opinion on Biological Therapy, 2020
Cameron J Turtle, Cassie K Chou
exaly